IP Life Science Expertise
Our IP practice provides analysis, assessment and strategic advice on life science Intellectual Property (IP). The practice is focused on both helping clients extract maximum value from their IP portfolios and supporting companies and investors conducting IP due diligence.
The service is designed to sit alongside what is offered by established patent firms. We do not file and maintain patents, but provide high-level strategic advice. For example, patent applications and procedures can take on a life of their own, with organizational inertia masking the need for a decision. We can provide a realistic, commercially relevant reality check, helping clients rationalize and prioritize IP assets.
We also undertake IP due diligence on behalf of an investor or acquirer to support a transaction or asset valuation.
Our technical areas of expertise span pharmaceutical chemistry, pharmacology, microbiology, biotechnology, genetic engineering, stem cells, physiology, pharmacogenomics, proteomics, plant and animal protection, medtech and medical instruments.
Case study: University IP portfolio triage
Working with King’s College London, Alacrita helped to evaluate and prioritize life science research projects for funding and commercial support with the objective to help promising intellectual property attract and secure investor and partner interest. This assignment was conducted over several months and was composed of three phases:
1. IP Audit
Using a project characterisation template running on a secure web-based platform, we surveyed several hundred PIs to identify potentially commercialisable projects with filed or patentable intellectual property. This encompassed the entire life science research portfolio of the university including therapeutics, biomarkers/diagnostics and medical devices.
2. Project Prioritization
Our consulting team, comprised of pharmaceutical, biotech, diagnostics and medtech industry specialists, analysed the information received from the PIs and validated it through a combination of internal analysis, external research and telephone interviews with PIs. Projects were scored according to their:
- Value in use
- Market attractiveness
This allowed projects to be ranked into priority categories for the next stage of the analysis.
3. Techno-Commercial Development Plans
Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected projects which would benefit most from focussed financial support for work to reach one or more value-creating milestones and thereby progress toward partnering and/or spin-out goals.
Further case studies regarding Research and IP evaluation are available here.
Related Case Studies
Conducting IP due diligence
We have conducted multiple due diligence projects, below are three examples: A financial investor needed an IP assessment on a late-stage cell therapy investment opportunity. An established medical...
Feasibility study – ophthalmic therapies
A leading research institute developing novel approaches for production of ophthalmic treatments asked Alacrita to conduct a market and competitive assessment of the current supplier base and prospective novel...
Economic impact of research institute
A UK public sector life sciences research institute focused on fundamental mammalian biology required an economic impact assessment of its science, as part of the evidence base accompanying...
Advising educational institutions on technology transfer
A university in a developing country wanted advice on best practice for IP protection and technology transfer. Solution The university didn’t have a critical mass of research activities...
Assessing antibody targets and IP risk
A mid-cap pharma company seeking to establish a biologics pipeline through partnership with a monoclonal antibody development boutique needed an assessment of target opportunities, soundness of third-party contracts,...
Commercial attractiveness of biomarkers for a start-up
A start-up that had developed a suite of proprietary antibody technologies needed help to identify accessible cell surface proteins for discovery of candidate therapeutic monoclonal antibody (mAb) targets...